The chemical class of AVL9 Inhibitors comprises a range of compounds distinguished by their capacity to modulate the activity of AVL9, a protein associated with cell migration. This diverse group of inhibitors is characterized by their unique mechanisms of action, each targeting different aspects of AVL9's function or the cellular pathways it influences. The primary focus of these inhibitors is to alter the dynamics of cell movement, a process fundamental to various biological phenomena. These inhibitors achieve this either by directly affecting AVL9's activity or by modifying the signaling pathways and cellular structures integral to its function.
The methodology behind the development of AVL9 inhibitors is rooted in understanding the intricacies of cell migration. This process involves a coordinated interplay of various cellular components, including the cytoskeleton, adhesion molecules, and a multitude of signaling molecules. AVL9 inhibitors are designed to target these components, thereby influencing the role of AVL9 in the migration process. Some inhibitors in this class function by directly binding to AVL9, altering its structural conformation or its interaction with other cellular constituents. This direct binding can impede the ability of AVL9 to perform its role in cell migration, effectively modulating the process. Other inhibitors operate by targeting key signaling pathways involved in cell migration. By modulating these pathways, these inhibitors can indirectly influence AVL9's activity, leading to altered cell migration dynamics. The development of AVL9 inhibitors signifies an important step in understanding cell motility. By elucidating the mechanisms through which these inhibitors act, researchers can gain deeper insights into the molecular processes governing cell migration. This understanding is crucial, as cell migration is not only a key aspect of physiological processes like tissue regeneration and immune response but also plays a pivotal role in the progression of various pathological conditions. The study of AVL9 inhibitors thus provides valuable information on the regulation of cell movement and the potential to explore new avenues in cellular biology. In essence, AVL9 inhibitors represent a crucial tool for probing the complex network of interactions that facilitate cell migration, offering a window into the molecular orchestration of this vital cellular process.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Could possibly inhibit AVL9 by directly affecting myosin II, altering cell motility processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Might directly impact AVL9 function by inhibiting ROCK and altering actin cytoskeleton dynamics. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Could inhibit Rac1, potentially affecting AVL9's function in cell migration directly. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Might directly affect AVL9 by inhibiting PI3K, altering cell survival and migration signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Could directly impact AVL9's role in cell migration by inhibiting the MEK/MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Potentially inhibits AVL9 by affecting cell migration processes via p38 MAPK inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Might directly alter AVL9's role in cell migration by disrupting PI3K signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Potentially impacts AVL9 directly by inhibiting Src family kinases, affecting cell migration pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Might modulate AVL9's role in cell migration directly by inhibiting JNK signaling. | ||||||
FAK Inhibitor 14 | 4506-66-5 | sc-203950 sc-203950A | 10 mg 50 mg | $109.00 $238.00 | 86 | |
Could directly impact AVL9's function in cell migration and adhesion by inhibiting focal adhesion kinase. | ||||||